Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 1998

View Archived Issues

Licensing opportunity from the NIH: technology for enhancing embryo implantation

Licensing opportunity from the NIH: method of protecting neural cells from apoptosis

Aminoacyl sulfamides synthesized at Cubist claimed for psoriasis

New K+ channel blockers for arrhythmias, ulcers and related disorders

Licensing opportunity from NIH: antiretroviral agents with unique mechanism of action

Chiron pinpoints site of HCV binding to host cells

HMR presents new agents for lipid disorders

Oncocidin A1: a novel microtubule-binding antitumor agent

InKine: Annual Report 1998

Selective, nonpeptide Y1 receptor antagonist reduces NPY-mediated food intake in rats

FDA okays U.S. portion of multinational study evaluating Theratope

Hungarian research team presents new antithrombotic thioglycosides

PIXY-321 performs favorably in children; compound unfortunately no longer in development

Prosorba Column recommended for approval by FDA advisory panel

Inhibition of ceramide glucosyltransferase as a novel therapeutic target

Continuing efforts at Parke-Davis result in structurally novel functional ETA receptor antagonist

Ibex Technologies: Q4 and year-end 1998 highlights

Positive CPMP opinion issued for Betaseron in new indication

Positive pivotal trial results for enzyme replacement therapy to be submitted with BLA

Synthelabo: nine-month highlights

Safety and efficacy of COX-2 inhibitor established in phase II trials

Japan Tobacco will acquire Torii in stock-purchase action

Targeted Genetics receives patent coverage for cellular therapy platform

Vivus: Q3 and nine-month highlights

Transkaryotic Therapies: Q3 1998 highlights

Liposomal GPI-2A associated with unexpected side effects in early clinical trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...